Treatment
Cisplatin clinical trials
We’re tracking 487 recruiting studies that include Cisplatin, each written for real people, not researchers, below.
Recruiting studies
- NCT05857631Recruiting
After-surgery radiation schedule for cervical or uterine cancers
This trial studies a shorter, focused radiation schedule given after surgery for certain higher-risk cervical or endometrial (uterine) cancers. It may help reduce cancer recurrence while checking side effects in the bladder and bowel area.
Navi Mumbai, MaharahstraAges 18–80 - NCT05862168RecruitingPhase 2
Tislelizumab with chemotherapy before surgery for oral cancer
This trial studies giving tislelizumab (an immune treatment) plus chemotherapy before surgery to shrink and treat locally advanced oral squamous cell cancer. It aims to improve tumor response and outcomes, while checking safety.
HangzhouAges 18–75 - NCT05903092RecruitingPhase 2
Monalizumab plus durvalumab for small cell lung cancer
This Phase 2 trial tests whether adding monalizumab to durvalumab (two immune-targeting medicines) can improve outcomes in people with small cell lung cancer. You may be able to join if you have certain stage of small cell lung cancer and have not had the specific prior treatments the study allows.
Indianapolis, IndianaAges 18 years+ - NCT05919030RecruitingPhase 3
Tislelizumab with chemoradiation for advanced esophagus cancer
This trial tests whether adding tislelizumab to chemoradiation as the first treatment helps people with advanced esophageal squamous cell cancer. It aims to improve how well the cancer responds when it cannot be cured with surgery or full-dose curative treatment.
Wuhan, HubeiAges 18 years+ - NCT05932212RecruitingPhase 2
Study drug for vulvar cancer after prior treatment failure
This Phase 2 trial tests AK104 in people with recurrent or metastatic vulvar cancer that cannot be cured with surgery or strong radiation. It may help shrink tumors or slow growth, especially if you’ve already tried standard treatments or couldn’t tolerate them.
Fuzhou, FujianAges 18–80 - NCT05932199RecruitingPhase 1/Phase 2
Durvalumab and tremelimumab before surgery for mesothelioma
This Phase 1/2 study tests the immune medicines durvalumab and tremelimumab, with or without chemotherapy, given before surgery for mesothelioma. It aims to shrink the tumor and improve safety and outcomes so more patients can have their cancer fully removed.
Durham, North CarolinaAges 18 years+ - NCT06006650RecruitingPhase 2
Neoadjuvant therapy for stage II-IVA esophageal cancer
This trial tests a treatment given before surgery for patients with a type of esophageal cancer called squamous cell carcinoma, stages II to IVA. The goal is to see if this approach can improve outcomes.
Xi'an, ShaanxiAges 18–75 - NCT06019130RecruitingPhase 2
Nivolumab for newly diagnosed nasopharyngeal cancer
This trial tests whether the immunotherapy drug nivolumab (Opdivo) can help treat nasopharyngeal cancer in both children and adults. It is for people who have just been diagnosed and have not yet received any cancer treatment.
AachenAges 3 years+ - NCT06022861RecruitingPhase 3
Study of LY01015 vs Opdivo with chemo for advanced esophageal cancer
This trial tests a new drug, LY01015, against Opdivo when both are given with chemotherapy for advanced or metastatic esophageal squamous cell carcinoma. It aims to see if LY01015 works as well as Opdivo and has similar safety.
GuangzhouAges 18–75 - NCT06026878RecruitingPhase 3
GNT induction treatment for advanced nasopharyngeal cancer
This trial tests a new drug combination called GNT given before standard chemoradiation for people with locally advanced nasopharyngeal cancer. It aims to improve treatment outcomes.
Xi'an, ShaanxiAges 18–75 - NCT06029270RecruitingPhase 2
Adding relatlimab to standard immunotherapy for nasopharyngeal cancer
This trial tests whether adding a new drug called relatlimab to the usual immunotherapy (nivolumab) helps people with nasopharyngeal cancer that has returned or spread. You will get standard chemotherapy plus nivolumab first, then if it works, you may be randomly assigned to get nivolumab alone or with relatlimab.
Dublin, CaliforniaAges 18 years+ - NCT06057935RecruitingPhase 2
Extra chemotherapy after surgery for peritoneal mesothelioma
This trial tests whether more chemotherapy after surgery can help people with a specific type of abdominal cancer (malignant peritoneal mesothelioma). It is for those who have had all visible tumor removed and have not had chemotherapy before.
Chicago, IllinoisAges 18 years+ - NCT06081673RecruitingPhase 2
Penpulimab plus chemo before and after surgery for head and neck cancer
This trial tests a combination of penpulimab (an immunotherapy drug) and chemotherapy before and after surgery for head and neck cancer. The goal is to see if this approach can improve treatment outcomes for people with resectable (removable by surgery) cancers.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT06087614RecruitingPhase 2
Higher-dose radiation for head and neck cancer
This trial tests a higher dose of radiation therapy that is adjusted based on oxygen levels in the tumor. It may help people with certain head and neck cancers that have not been treated before.
DelhiAges 18–70 - NCT06092957RecruitingPhase 3
Reduced radiation after chemo-immunotherapy for high-risk nasopharyngeal cancer
This trial tests whether a lower dose of radiation, with or without additional chemo-immunotherapy, works as well as the standard full-dose chemoradiation for people with advanced nasopharyngeal cancer who had a complete response after initial chemo-immunotherapy.
Guangzhou, GuangdongAges 18–70 - NCT06100497RecruitingPhase 2
PD-1 plus chemo for advanced head and neck cancer
This trial tests a combination of immunotherapy (PD-1) and chemotherapy for people with advanced head and neck cancers that are poorly differentiated. The goal is to see if the combination helps shrink tumors before possible surgery or radiation.
Beijing, Beijing MunicipalityAges 18 years+ - NCT06102395RecruitingPhase 3
Pembrolizumab plus chemo before surgery for advanced head and neck cancer
This trial tests whether adding pembrolizumab (an immunotherapy drug) to standard chemotherapy before surgery can help people with advanced head and neck cancer. It aims to see if the combination is more effective than chemotherapy alone.
Beijing, Beijing MunicipalityAges 18 years+ - NCT06123884RecruitingPhase 2/Phase 3
BAT1308 plus chemotherapy for PD-L1-positive cervical cancer
This clinical trial tests a new combination therapy (BAT1308 plus chemotherapy, with or without Avastin) for women with advanced cervical cancer that is PD-L1-positive and has not been previously treated with systemic therapy. The goal is to see if this combination can shrink tumors or slow disease progression.
Wuhan, HubeiAges 18–70 - NCT06138561Recruiting
Bladder cancer treatment study for older adults
This study looks at how well different treatments work for older adults with bladder cancer that has spread and who cannot take cisplatin. It also checks if geriatric assessments help guide care.
Boston, MassachusettsAges 65 years+ - NCT06140966RecruitingPhase 2
Daratumumab and Carfilzomib combo for high-risk multiple myeloma
This trial tests a combination of the drugs daratumumab, carfilzomib, lenalidomide, and dexamethasone given before and after a stem cell transplant for people with ultra high-risk multiple myeloma. The goal is to see if this regimen is safe and more effective than standard treatments.
Wuhan, HubeiAges 18–70 - NCT06144736RecruitingPhase 2
Surgery for stage 2 seminoma testicular cancer trial
This trial is testing whether removing affected lymph nodes with surgery (RPLND) works well alone for seminoma testicular cancer that has spread to nearby nodes but is still relatively small. It is for patients who have not had extensive chemo or radiation.
DüsseldorfAges 18–99 - NCT06173986RecruitingPhase 1/Phase 2
Immunotherapy plus chemoradiation for advanced esophageal cancer
This trial tests whether adding immunotherapy to standard chemoradiation can help people with unresectable locally advanced esophageal cancer. It aims to improve outcomes for those who cannot have surgery.
ShanghaiAges 18–75 - NCT06197776Recruiting
Predicting treatment success for advanced nasopharyngeal cancer
This study uses advanced testing (multi-omics) to predict if combining chemoradiation with immunotherapy works better for nasopharyngeal cancer that has returned or spread. It aims to find the right treatment for each person.
Guangzhou, GuangdongAges 18–70 - NCT06208826RecruitingPhase 2
Immunotherapy maintenance after surgery for head and neck cancer
This trial looks at whether continuing immunotherapy can help keep cancer from coming back in people with head and neck cancer who had a good response to chemo-immunotherapy before surgery. You would have already had surgery, and now the study tests a maintenance treatment to strengthen your immune system's fight against any remaining cancer cells.
Tianjin, Tianjin MunicipalityAges 18–80
Common questions
- Are there clinical trials studying Cisplatin?
- Yes. Clin2 currently lists 487 recruiting studies that include Cisplatin, drawn from the U.S. registry and rewritten for real people so you can see what each is testing and who it's for.
- How do I know if I qualify for a Cisplatin trial?
- Each study lists its own eligibility criteria — rules about condition, age, and prior treatments. On every Clin2 trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Is Cisplatin an approved treatment?
- A drug being studied in a trial may be investigational (still being tested) or already approved and being studied for a new use. Each study page explains what phase it's in. Clin2 does not provide medical advice — talk with your doctor about whether Cisplatin or a specific trial is right for you.
Related treatments
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. A drug appearing here is being studied in a trial and may be investigational. Talk with your doctor about whether a specific treatment or trial is right for you.